Myeloperoxidase in atrial fibrillation: association with progression, origin and influence of renin-angiotensin system antagonists.

Erik HolzwirthJelena KornejSandra ErbsDanilo ObradovicAndreas BollmannGerhard HindricksHolger ThielePetra Büttner

Published in: Clinical research in cardiology : official journal of the German Cardiac Society (2019)

The pro-fibrotic enzyme MPO is generally elevated in AF patients irrespective of AF type, the presence of LVA or midterm rhythm outcome. Our data suggest that MPO may directly originate from the LA. RAS-A decrease peripheral MPO levels in AF patients.

Keyphrases

atrial fibrillation
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
heart failure
blood pressure
left atrial
machine learning
patient reported outcomes
catheter ablation
mitral valve
oral anticoagulants
direct oral anticoagulants
big data
idiopathic pulmonary fibrosis